View in EDS

Palivizumab use in very premature infants in the neonatal intensive care unit.

Saved in:
Bibliographic Details
Title: Palivizumab use in very premature infants in the neonatal intensive care unit.
Authors: Wu S (AUTHOR), Bonaparte J (AUTHOR), Pyati S (AUTHOR)
Source: Pediatrics. 2004 Nov Supplement, Vol. 114 Issue 5, pe554-6. 1p.
Abstract: OBJECTIVE: The purpose of this study was to determine the ability of young hospitalized premature (born < or =30 weeks' gestational age) infants to achieve serum levels of palivizumab that are protective against RSV infection. METHODS: Palivizumab, 15 mg/kg per dose intramuscularly, was administered every 28 days to stable premature infants who were hospitalized in the neonatal intensive care unit starting at 1 month of postnatal life. Palivizumab concentrations were assayed in serum samples that were drawn from infants who remained in the hospital at 14 days (midpoint concentration) and at 28 days (trough concentration) after each dose was administered. RESULTS: The gestational age of the 24 infants who were enrolled was 27.5 +/- 1.8 weeks (mean +/- standard deviation), and birth weight was 928 +/- 159 g. Midpoint palivizumab concentrations in the 24 infants after the first dose were 45.6 +/- 13.0 microg/mL; 71% (17 of 24) of the infants maintained optimal palivizumab concentrations (> or =40 microg/mL). The concentrations dropped subsequently; trough concentrations just before the second dose were 32.2 +/- 10.5 microg/mL, and only 23% (5 of 22) of the infants had concentrations in the optimal range. Sixteen infants were given 2 doses and 6 were given three doses of palivizumab while in the neonatal intensive care unit. Midpoint concentrations after the second dose were significantly higher than those after the first dose. Likewise, trough concentrations before the third dose were 51.9 +/- 7.8 microg/mL and higher than those before the second dose; the concentrations were >40 microg/ml in all 6 infants tested. CONCLUSIONS: Very premature infants had sustained optimal protective serum concentrations only after the second dose of palivizumab; 77% of infants tested had trough concentrations <40 microg/mL before the second dose. Additional studies are needed to establish the optimal timing of the initial dose and optimal dosing interval of palivizumab in this most vulnerable population. [ABSTRACT FROM AUTHOR]
Copyright of Pediatrics is the property of American Academy of Pediatrics and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 106627480
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Palivizumab use in very premature infants in the neonatal intensive care unit.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Wu+S%22&quot;&gt;Wu S&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bonaparte+J%22&quot;&gt;Bonaparte J&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pyati+S%22&quot;&gt;Pyati S&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Pediatrics%22&quot;&gt;Pediatrics&lt;/searchLink&gt;. 2004 Nov Supplement, Vol. 114 Issue 5, pe554-6. 1p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: OBJECTIVE: The purpose of this study was to determine the ability of young hospitalized premature (born &lt; or =30 weeks&#39; gestational age) infants to achieve serum levels of palivizumab that are protective against RSV infection. METHODS: Palivizumab, 15 mg/kg per dose intramuscularly, was administered every 28 days to stable premature infants who were hospitalized in the neonatal intensive care unit starting at 1 month of postnatal life. Palivizumab concentrations were assayed in serum samples that were drawn from infants who remained in the hospital at 14 days (midpoint concentration) and at 28 days (trough concentration) after each dose was administered. RESULTS: The gestational age of the 24 infants who were enrolled was 27.5 +/- 1.8 weeks (mean +/- standard deviation), and birth weight was 928 +/- 159 g. Midpoint palivizumab concentrations in the 24 infants after the first dose were 45.6 +/- 13.0 microg/mL; 71% (17 of 24) of the infants maintained optimal palivizumab concentrations (&gt; or =40 microg/mL). The concentrations dropped subsequently; trough concentrations just before the second dose were 32.2 +/- 10.5 microg/mL, and only 23% (5 of 22) of the infants had concentrations in the optimal range. Sixteen infants were given 2 doses and 6 were given three doses of palivizumab while in the neonatal intensive care unit. Midpoint concentrations after the second dose were significantly higher than those after the first dose. Likewise, trough concentrations before the third dose were 51.9 +/- 7.8 microg/mL and higher than those before the second dose; the concentrations were &gt;40 microg/ml in all 6 infants tested. CONCLUSIONS: Very premature infants had sustained optimal protective serum concentrations only after the second dose of palivizumab; 77% of infants tested had trough concentrations &lt;40 microg/mL before the second dose. Additional studies are needed to establish the optimal timing of the initial dose and optimal dosing interval of palivizumab in this most vulnerable population. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Pediatrics is the property of American Academy of Pediatrics and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=106627480
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1542/peds.2004-0226
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: e554
    Titles:
      – TitleFull: Palivizumab use in very premature infants in the neonatal intensive care unit.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wu S
      – PersonEntity:
          Name:
            NameFull: Bonaparte J
      – PersonEntity:
          Name:
            NameFull: Pyati S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 11
              Text: 2004 Nov Supplement
              Type: published
              Y: 2004
          Identifiers:
            – Type: issn-print
              Value: 00314005
          Numbering:
            – Type: volume
              Value: 114
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Pediatrics
              Type: main
ResultId 1